AbbVie Inc. (ABBV) |
|
141.29 -0.15 (-0.11%)
|
08-19 00:59 |
|
Open: |
141.49 |
Pre. Close: |
141.44 |
|
High:
|
141.58 |
Low:
|
139.82 |
|
Volume:
|
3,127,596 |
Market Cap:
|
249,815(M) |
|
|
|
|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
142.97 - 143.7 |
143.7 - 144.29 |
|
Low:
|
138.88 - 139.65 |
139.65 - 140.28 |
|
Close:
|
140.34 - 141.54 |
141.54 - 142.53 |
|
Technical analysis |
as of: 2022-08-18 3:50:29 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 172.96 One year: 180.42 |
| Support: |
Support1: 137.77 Support2: 114.62 |
| Resistance: |
Resistance1: 148.09 Resistance2: 154.47 |
| Pivot: |
141.06 |
| Moving Average: |
MA(5): 142.02 MA(20): 143.31
MA(100): 150.65 MA(250): 136.88  |
| MACD: |
MACD(12,26): -2 Signal(9): -2.1 |
| Stochastic oscillator: |
%K(14,3): 32.7 %D(3): 30.7 |
| RSI: |
RSI(14): 40 |
| 52-week: |
High: 175.91 Low: 105.55 |
| Average Vol(K): |
3-Month: 5,913 (K) 10-Days: 3,786 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABBV ] has closed below upper band by 47.4%. Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 18 Aug 2022
ABBV: 1 Stock You Shouldn't Sell No Matter What - StockNews.com
Tue, 16 Aug 2022
ABBV: 5 Income Stocks to Turn to When Times Are Tough - StockNews.com
Tue, 16 Aug 2022
ABBV: 3 Blue-Chip Stocks That'll Help Your Portfolio Survive - StockNews.com
Tue, 16 Aug 2022
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq
Mon, 15 Aug 2022
How To Buy Dividend Aristocrat ABBV For A 10% Discount, Or Achieve A 9% Return - Barchart
Thu, 11 Aug 2022
September 30th Options Now Available For AbbVie (ABBV) - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
1,770 (M) |
| Shares Float |
1,770 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
71.1 (%) |
|
Shares Short
|
14,030 (K) |
|
Shares Short P.Month
|
13,520 (K) |
Stock Financials |
|
EPS
|
7.07 |
|
EPS Est Next Qtl
|
1.44 |
|
EPS Est This Year
|
5.53 |
|
EPS Est Next Year
|
6.55 |
|
Book Value (p.s.)
|
9.22 |
|
Profit Margin (%)
|
22 |
|
Operating Margin (%)
|
37 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
4.5 |
|
Gross Profit (p.s.)
|
21.96 |
|
Sales Per Share
|
32.4 |
|
EBITDA (p.s.)
|
16.64 |
|
Qtrly Earnings Growth
|
21.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
19.97 |
|
PEG Ratio
|
-37.8 |
|
Price to Book value
|
15.31 |
|
Price to Sales
|
4.35 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
1.4 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.9% |
|
Dividend Pay Date
|
2022-02-14 |
|
Ex-Dividend Date
|
2022-01-12 |
|
7 Binary Options
|
|
Your Ad Here
|
|
